| http://purl.uniprot.org/citations/8471066 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/8471066 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/8471066 | http://www.w3.org/2000/01/rdf-schema#comment | "Normal rat kidney fibroblasts (NRK-49F cells) stimulated with interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) produced mainly cytokine-induced neutrophil chemoattractant (CINC) which is the rat counterpart of human gro/melanoma growth stimulatory activity. In addition, the cytokine-stimulated cells produced two minor neutrophil chemoattractants which are highly related to murine macrophage inflammatory protein-2 in their NH2-terminal amino acid sequences. IL-1 beta was a stronger stimulator than TNF-alpha, and addition of both the cytokines into the NRK-49F cell culture caused an additive stimulation for rat gro/CINC production. The anti-inflammatory steroids (dexamethasone, prednisolone and hydrocortisone) at 10(-9)-10(-6) M significantly suppressed the production of rat gro/CINC by the IL-1 beta-stimulated NRK-49F cells in a dose-dependent manner. The relative potencies of the inhibitory activity of the steroids on the rat gro/CINC production were dexamethasone > prednisolone > hydrocortisone. On the other hand, the non-steroidal anti-inflammatory drugs (indomethacin and piroxicam) at 10(-7)-10(-5) M showed no apparent inhibitory effect on rat gro/CINC production by NRK-49F cells stimulated with IL-1 beta."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.org/dc/terms/identifier | "doi:10.1016/0006-2952(93)90041-t"xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.org/dc/terms/identifier | "doi:10.1016/0006-2952(93)90041-t"xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Kato H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Kato H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Nakagawa H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Nakagawa H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Watanabe K."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Watanabe K."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Hatakeyama S."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Hatakeyama S."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Ikesue A."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Ikesue A."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Komorita N."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Komorita N."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Gotoda T."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Gotoda T."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Miyai H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/author | "Miyai H."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/date | "1993"xsd:gYear |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/date | "1993"xsd:gYear |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/name | "Biochem. Pharmacol."xsd:string |
| http://purl.uniprot.org/citations/8471066 | http://purl.uniprot.org/core/name | "Biochem. Pharmacol."xsd:string |